Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 21, 2025

Stock market today: Dow, S&P 500, Nasdaq bounce but end turbulent week with sharp losses

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq bounce but end turbulent week with sharp losses US stocks climbed on Friday to close a turbulent session in the green amid rising optimism for a December interest rate cut, while bitcoin (BTC-USD) kept tumbling amid a brutal stretch for cryptocurrencies…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Tech stocks still set for record $75 billion inflow in 2025

    80% confidence

  • Q3 strength positions company well for holiday season and gives confidence to raise full year outlook

    80% confidence

  • Oil prices to drop consistently through 2026 before picking back up in 2027

    80% confidence

  • He sees room for a rate cut in the near term

    80% confidence

  • Consumer sentiment deteriorated further in November to reading of 51

    80% confidence

  • After federal shutdown ended, sentiment lifted slightly from mid-month reading

    80% confidence

  • Oil overhang to reach up to 4 million barrels per day in 2026

    80% confidence

  • Recent company hire did not take intellectual property from TSMC

    80% confidence

Data points we hold from this source

Dow Jones Industrial Average · closing price46245.41 USD
Dow Jones Industrial Average · points change493.15 points
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq bounce but end turbulent week with sharp losses — Source | Via News | Finance Via News